Trials / Completed
CompletedNCT01543490
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 558 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISV-305 | Dexamethasone in DuraSite® 2 twice daily for 2 weeks |
| OTHER | Vehicle | Vehicle twice daily for 2 weeks |
Timeline
- Start date
- 2018-03-30
- Primary completion
- 2020-02-04
- Completion
- 2020-02-04
- First posted
- 2012-03-05
- Last updated
- 2021-11-19
- Results posted
- 2021-03-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01543490. Inclusion in this directory is not an endorsement.